Gold prices edge higher on raised Fed rate cut hopes
Akero Therapeutics Inc . stock (NASDAQ:AKRO) reached a new 52-week high this trading session, with shares climbing to an impressive $56.86. With a market capitalization of $1.83 billion, the stock has shown remarkable resilience, maintaining a negative beta of -0.2, indicating it often moves contrary to broader market trends according to InvestingPro data. This peak represents a significant milestone for the biotechnology company, which has seen a robust 1-year change, with an 18.35% increase in its stock price. Investors are closely monitoring AKRO as it continues to make strides in its clinical developments, with analyst price targets ranging from $35 to $65. The company's strong financial position is evident in its impressive current ratio of 17.25, demonstrating robust liquidity. Want deeper insights? InvestingPro subscribers have access to over 8 additional key tips and metrics about AKRO's financial health and market position.
In other recent news, Akero Therapeutics has reported significant findings from its Phase 2b SYMMETRY study. The study showed a statistically significant reversal in fibrosis for patients treated with the company's leading drug candidate, efruxifermin (EFX). In addition, Akero Therapeutics has made progress with its Phase 3 SYNCHRONY Outcomes study, which is evaluating the efficacy of EFX in patients with fibrosis stage 4 (F4).
H.C. Wainwright has reaffirmed its Buy rating for Akero Therapeutics, highlighting the recent completion of patient enrollment for the Phase 3 SYNCHRONY Real-World study. Meanwhile, Citi has initiated coverage on Akero Therapeutics with a positive outlook, assigning the stock a Buy rating based on the potential of Akero's drug efruxifermin.
On the other hand, Keros Therapeutics has voluntarily paused dosing in certain arms of its Phase 2 TROPOS Trial due to unanticipated cases of pericardial effusion among participants. The company is actively collaborating with trial investigators, the U.S. Food and Drug Administration (FDA), and other regulatory authorities to resolve the issue swiftly.
These are recent developments that provide an insight into the progress and challenges of both Akero Therapeutics and Keros Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.